.jpg)
Oops! Something went wrong while submitting the form.
Services
There is no single dysautonomia medication. There is a small set of options — beta-blockers, ivabradine, fludrocortisone, midodrine, pyridostigmine, desmopressin and others — and each works on a different part of the autonomic picture. Response is individual. A medication that stabilises one person's standing heart rate may worsen another's fatigue. A volume-expander that raises one person's blood pressure may produce headaches in another. The dose that helps in one body is intolerable in another.
Medication management in the dysautonomia pathway is the clinical work of choosing which pharmacological option fits this picture, at what dose, in what combination, and how to know whether it is doing what was intended. It is not a starting point. It is one part of the broader plan — usually layered onto lifestyle structure, fluid and electrolyte strategy, graded exercise and the rest of the team's input, not in place of them.
This service is for people in the dysautonomia pathway whose autonomic symptoms — standing heart rate, blood pressure, brain fog, fatigue, exercise intolerance — are limiting daily life despite non-medication strategies. It is also for people for whom medication has been tried previously without clear improvement, and where careful re-review is warranted.
The consultation begins with the autonomic and clinical picture as it currently stands. Standing data, fluid intake, current medications, prior medication trials, response to each, comorbidities (mast-cell, gastrointestinal, hormonal, neurological), prior pathology. The point is to know what the medication is being asked to do.
Dysautonomia is not one shape. The consultation looks at which sub-pattern dominates — high-flow, hypovolaemic, hyperadrenergic, neuropathic, post-viral, post-vaccine, hormonally-driven — and which medication options fit the pattern that is actually present.
A medication plan is built around the read. Starting dose, escalation schedule, monitoring strategy and the symptoms that will be tracked are named explicitly. Where a non-medication change would be the right thing to try first, that is named too.
The plan is built with the rest of the biio. team in view. Where dietetics, exercise physiology or physiotherapy is already in motion, medication timing is built around those — not against them. The record holds the reasoning so the next clinician can see why a particular drug was chosen.
Each trial has a review point. If the medication is doing what was intended, that is recorded; if it is not, the dose is adjusted or the medication is changed against the reason, not by adding another agent on top. Side-effects are tracked alongside benefit.
Over time, a working medication picture is established — what dose, what combination, what to do during a flare or an intercurrent illness. Clinical contact moves to background review as that picture stabilises.
When medication management is going well, the autonomic picture across a day becomes more predictable. Standing costs less. Brain fog lifts faster. The patient stops trialling new drugs every few weeks because the working combination has been found and the reasoning is documented.
Medication does not cure dysautonomia, and the right medication does not, by itself, resolve a presentation that is also shaped by deconditioning, post-viral physiology, mast-cell activity, hormonal change, sleep, nutrition and stress load. What it can do is reduce the pharmacological piece of the picture so the rest of the work has somewhere to land.